Vascular Effects of High-Salt After Preeclampsia

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorAnna Stanhewicz, PhD

About this trial

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear.

The purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function.

In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.

Eligibility criteria

Qualifiers

women who had preeclampsia and women who did not have preeclampsia

12 weeks to 5 years postpartum

18-45 years old

Disqualifiers

history of hypertension or metabolic disease before pregnancy

history of gestational diabetes

history of gestational hypertension without preeclampsia

skin diseases

Trial design

Treatments tested in this trial

  • Eplerenone

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Anna Stanhewicz, PhD

Lead sponsor

University of Iowa

Sponsor institution